Sanofi Teams With Innate Pharma to Develop Cancer Drugs

Sanofi Extends Warp Drive Development Deal for Five Years

Sanofi has teamed up with Innate Pharma SA in an effort to develop cancer treatments using the body’s own immune system.

The two French companies will develop up to two treatments using antibodies to engage so-called natural-killer cells to attack tumors, according to a statement Sunday. Innate Pharma surged as much as 12 percent to 14.25 euros in Paris. Sanofi showed little change, trading at 74.65 euros.

The agreement signals Sanofi aims to capture a larger slice of the spending on cancer treatments, which has grown by 6.5 percent annually in the past five years and reached $100 billion in 2014, according to the IMS Institute for Healthcare Informatics. The U.S. and the five largest countries in Europe account for two-thirds of the total spending, the report said.

Paris-based Sanofi will lead development, manufacturing and marketing of any products. Innate, based in Marseille, could receive payments of as much 400 million euros ($437 million) as well as royalties on net sales.

Before it's here, it's on the Bloomberg Terminal.